Abstract
We examined blood and urine concentrations of repetitive doses of inhaled salbutamol
in relation to the existing cut-off value used in routine doping control. We compared
the concentrations in asthmatics with regular use of beta2-agonists prior to study
and healthy controls with no previous use of beta2-agonists. We enrolled 10 asthmatics
and 10 controls in an open-label study in which subjects inhaled repetitive doses
of 400 microgram salbutamol every second hour (total 1 600 microgram), which is the
permitted daily dose by the World Anti-Doping Agency (WADA). Blood samples were collected
at baseline, 30 min, 1, 2, 3, 4, and 6 h after the first inhalations. Urine samples
were collected at baseline, 0–4 h, 4–8 h, and 8–12 h after the first inhalations.
Median urine concentrations peaked in the period 4–8 h after the first inhalations
in the asthmatics and between 8–12 h in controls and the median ranged from 268 to
611 ng×mL−1. No samples exceeded the WADA threshold value of 1 000 ng×mL−1 when corrected for the urine specific gravity. When not corrected one sample exceeded
the cut-off value with urine concentration of 1 082 ng×mL−1. In conclusion we found no differences in blood and urine concentrations between
asthmatic and healthy subjects. We found high variability in urine concentrations
between subjects in both groups. The variability between subjects was still present
after the samples were corrected for urine specific gravity.
Key words
beta2-agonists - pharmacokinetics - doping - asthma
References
- 1
Anderson PJ.
Pharmacokinetics of (R,S)-albuterol after aerosol inhalation in healthy adult volunteers.
J Pharm Sci.
1998;
87
841-844
- 2
Anderson SD, Argyros GJ, Magnussen H, Holzer K.
Provocation by eucapnic voluntary hyperpnoea to identify exercise induced bronchoconstriction.
Br J Sports Med.
2001;
35
344-347
- 3
ATS/ERS recommendations for standardized procedures for the online and offline measurement
of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005.
Am J Respir Crit Care Med.
2005;
171
912-930
- 4
Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, Ohta K,
O'Byrne P, Pedersen SE, Pizzichini E, Sullivan SD, Wenzel SE, Zar HJ.
Global strategy for asthma management and prevention: GINA executive summary.
Eur Respir J.
2008;
31
143-178
- 5
Berges R, Segura J, Ventura R, Fitch KD, Morton AR, Farré M, Mas M, de La Torre X.
Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma
treatment.
Clin Chem.
2000;
46
1365-1375
- 6
Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, Bouglas G, Muers M, Smith D,
White J.
Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive
airways disease: a systemic review of the literature.
Health Technol Assess.
2001;
5
1-149
- 7
Carlsen KH, Anderson SD, Bjermer L, Bonini S, Brusasco V, Canonica W, Cummiskey J,
Delgado L, Del Giacco SR, Drobnic F, Haahtela T, Larsson K, Palange P, Popov T, van
Cauwenberge P.
Exercise-induced asthma, respiratory and allergic disorders in elite athletes: epidemiology,
mechanisms and diagnosis: part I of the report from the Joint Task Force of the European
Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology
(EAACI) in cooperation with GA2LEN.
Allergy.
2008;
63
387-403
- 8 Dreborg S. The skin prick test: methodological studies and clinical applications.
Linköping University, Linköping, Sweden; 1987
- 9
Elers J, Pedersen L, Henninge J, Lund TK, Hemmersbach P, Dalhoff K, Backer V.
Blood and urinary concentrations of salbutamol in asthmatic subjects.
Med Sci Sports Exerc.
2010;
42
244-249
- 10
Elers J, Strandbygaard U, Pedersen L, Backer V.
Daily use of salmeterol causes tolerance to bronchodilation with terbutaline in asthmatic
subjects.
Open Respir Med J.
2010;
21; 4
48-50
- 11
Hancox RJ, Subbarao P, Kamada D, Watson RM, Hargreave FE, Inman MD.
Beta2-agonist tolerance and exercise-induced bronchospasm.
Am J Respir Crit Care Med.
2002;
165
1068-1070
- 12
Harriss DJ, Atkinson G.
International Journal of Sports Medicine – Ethical Standards in Sport and Exercise
Science Research.
Int J Sports Med.
2009;
30
701-702
- 13
Helenius IJ, Tikkanen HO, Haahtela T.
Association between type of training and risk of asthma in elite athletes.
Thorax.
1997;
52
157-160
- 14
Helenius IJ, Tikkanen HO, Sarna S, Haahtela T.
Asthma and increased bronchial responsiveness in elite athletes: atopy and sport event
as risk factors.
J Allergy Clin Immunol.
1998;
101
646-652
- 15
Nysom K, Ulrik CS, Hesse B, Dirksen A.
Published models and local data can bridge the gap between reference values of lung
function for children and adults.
Eur Respir J.
1997;
10
1591-1598
- 16
Pichon A, Venisse N, Krupka E, Pérault-Pochat MC, Denjean A.
Urinary and blood concentrations of beta-2-agonists in trained subject: comparison
between routes of use.
Int J Sports Med.
2006;
27
187-192
- 17
Schweizer C, Saugy M, Kamber M.
Doping test reveals high concentrations of salbutamol in a Swiss track and field athlete.
Clin J Sport Med.
2004;
14
312-315
- 18
Sporer BC.
Dose response of inhaled salbutamol on exercise performance and urine concentrations.
Med Sci Sports Exerc.
2008;
40
149-157
- 19
Sporer BC.
Inhaled salbutamol and doping control: effects of dose on urine concentrations.
Clin J Sport Med.
2008;
18
282-285
- 20
The Global Strategy for Asthma Management and Prevention.
.
Global Initiative for Asthma (GINA).
2008;
available on
http://www.ginasthma.com
- 21
Thomsen SF, Ulrik CS, Larsen K, Backer V.
Change in prevalence of asthma in Danish children and adolescents.
Ann Allergy Asthma Immunol.
2004;
92
506-511
- 22
Ventura R, Segura J, Berges R, Fitch KD, Morton AR, Berruezo S, Jiménez C.
Distinction of inhaled and oral salbutamol by urine analysis using conventional screening
procedures for doping control.
Ther Drug Monit.
2000;
22
277-282
- 23
Yan K, Salome C, Woolcock AJ.
Rapid method for measurement of bronchial responsiveness.
Thorax.
1983;
38
760-765
Correspondence
Jimmi ElersMD
Bispebjerg Hospital
Respiratory Research Unit
Bispebjerg Bakke 23
DK-2100 København NV
Denmark
Telefon: +45/353/132 08
Fax: +45/353/121 79
eMail: elers@dadlnet.dk